688298 东方生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.270-7.514-5.09827.533105.774
总资产报酬率 ROA (%)-2.726-6.191-4.03621.01378.408
投入资产回报率 ROIC (%)-3.058-6.908-4.61325.748101.227

边际利润分析
销售毛利率 (%)41.63731.74143.01150.79373.790
营业利润率 (%)-34.863-69.914-46.80028.83556.803
息税前利润/营业总收入 (%)-45.751-96.948-82.88821.29957.401
净利润/营业总收入 (%)-34.411-68.705-50.99923.92248.585

收益指标分析
经营活动净收益/利润总额(%)96.65472.19845.059149.748100.555
价值变动净收益/利润总额(%)-4.477-6.908-8.1700.3110.194
营业外收支净额/利润总额(%)0.2161.1075.045-2.326-0.111

偿债能力分析
流动比率 (X)4.2793.3055.4303.8393.948
速动比率 (X)3.8573.0495.1113.6503.719
资产负债率 (%)13.51816.09916.07622.24223.262
带息债务/全部投入资本 (%)4.2876.1977.7529.8400.899
股东权益/带息债务 (%)2,208.4201,491.2711,180.349910.40610,972.267
股东权益/负债合计 (%)626.724509.926514.172342.869328.380
利息保障倍数 (X)4.2313.6932.467-3.09686.813

营运能力分析
应收账款周转天数 (天)91.19094.411113.14130.66632.042
存货周转天数 (天)220.708208.859299.88137.65257.548